Xi'an Shiyou Daxue Xuebao (Ziran Kexue Ban)/
Journal of Xi'an Shiyou University, Natural Sciences Edition
ISSN: 1673-064X
E-Publication: Online Open Access
Vol: 68 Issue 12 | 2025
DOI: 10.5281/zenodo.18030031

INTRAVENOUS THERAPY IN MODERN CLINICAL PRACTICE: A COMPREHENSIVE REVIEW OF FLUIDS, IRON, AND VITAMINS

SARAH MUSTAPHA IBRAHIM
Faculty of Pharmacy, Arab International University, Damascus, Syria.

GHASSAN SHANNAN
BSc, PhD, Faculty of Pharmacy Dean, Arab International University, Damascus, Syria.

ZEINA S. MALEK
PhD, Physiology Professor, Faculty of Pharmacy, Arab International University, Damascus, Syria.
Email: z-malek@aiu.edu.sy, ORCID:0009-0006-7075-7991

Dr. NASSER THALLAJ*
Professor, Pharmaceutical Chemistry and Drug Quality Control Department, Faculty of Pharmacy, Arab International University, Damascus, Syria. *Corresponding Author Email : n-thallaj@aiu.edu.sy,
ORCID: 0000-0002-6279-768X, [1]Scopus ID:59803999800, [2]Scopus ID: 10044360600

Abstract

Intravenous (IV) therapy constitutes a foundational and indispensable modality in contemporary medical practice, offering direct and controlled systemic delivery of therapeutic agents with unparalleled pharmacokinetic precision. This comprehensive review synthesizes the physiological principles, clinical evidence, and practical protocols governing the three primary domains of modern IV therapy: fluid resuscitation, iron replacement, and vitamin/nutrient administration. We detail the evidence-based application of crystalloid solutions—isotonic, hypotonic, and hypertonic—for targeted volume and tonicity management. The analysis highlights the paradigm shift toward IV iron formulations, such as ferric carboxymaltose, for efficiently correcting iron deficiency anemia, particularly in inflammatory states or malabsorption, supported by survey data showing high rates of biochemical correction (87%) and symptomatic improvement (66%). Furthermore, the review critically delineates established, life-saving applications of IV vitamins (e.g., thiamine in Wernicke's encephalopathy) from the evidence-light landscape of wellness-oriented nutrient infusions. Emphasis is placed on the critical importance of rigorous patient selection, adherence to sterile compounding standards (USP <797>), utilization of smart infusion technology, and vigilant monitoring to ensure safety and efficacy. The article concludes by identifying key research priorities, including the development of safer formulations and biomarker-stratified trials, to advance personalized IV therapy. Ultimately, IV therapy remains a cornerstone of medical intervention, whose optimal utility is realized through a meticulous, evidence-driven, and patient-centered approach.

Keywords: Intravenous Therapy, Fluid Resuscitation, Iron Deficiency Anemia, Parenteral Nutrition, Pharmacokinetics, Hepcidin, Crystalloid Solutions, Vitamin Infusion, Patient Safety, Evidence-Based Practice.

INTRODUCTION

Intravenous (IV) therapy represents a fundamental and sophisticated cornerstone of contemporary medical practice, enabling the direct, controlled, and immediate delivery of therapeutic agents into the systemic circulation.[1-3] By circumventing the physiological barriers of the gastrointestinal tract—first-pass metabolism, variable absorption, and enzymatic degradation—this route guarantees 100% bioavailability, precise dose

Xi'an Shiyou Daxue Xuebao (Ziran Kexue Ban)/
Journal of Xi'an Shiyou University, Natural Sciences Edition
ISSN: 1673-064X
E-Publication: Online Open Access
Vol: 68 Issue 12 | 2025
DOI: 10.5281/zenodo.18030031

titration, and rapid onset of action.[4-8]] These unparalleled pharmacokinetic advantages establish IV therapy as an indispensable intervention across the clinical spectrum, from emergency resuscitation for shock and severe dehydration to the management of chronic conditions like iron deficiency anemia and complex nutritional deficits.[9-13]

The historical trajectory of IV therapy, from its perilous 17th-century origins to its current status as a routine, evidence-based procedure, underscores a journey defined by overcoming challenges in asepsis, solution compatibility, and device technology. [14-18] Today, its practice is underpinned by a rigorous scientific foundation that integrates principles of vascular access, fluid dynamics, sterile pharmaceutical compounding, and advanced infusion technology. [19-22]] The selection of an appropriate vascular access device—ranging from short-term peripheral catheters to long-term central lines—is a critical first decision dictated by the therapy's duration, osmolarity, and vesicant potential, each carrying distinct risk profiles for infection, thrombosis, and mechanical complications. [23-29]

This scientific review provides a comprehensive, critical synthesis of modern IV therapy, structured around its three most pivotal and distinct therapeutic classes: resuscitation fluids, iron preparations, and vitamin complexes.[30-36]] We first examine the physiological rationale and evidence-based protocols for **IV fluid therapy**, detailing the classification of crystalloid solutions—isotonic, hypotonic, and hypertonic—and their specific roles in volume expansion, maintenance, and the correction of tonicity disorders.[37-42] Second, we explore the paradigm shift in **IV iron therapy**, analyzing the pathophysiology of iron deficiency—particularly the role of the hepcidin-ferroportin axis in functional deficiency—and the pharmacokinetics, efficacy, and safety profiles of modern carbohydrate-shelled formulations that allow for rapid, high-dose correction.[43-48] Third, we critically assess **IV vitamin and nutrient therapy**, delineating well-established, life-saving applications (e.g., thiamine for Wernicke's encephalopathy) from the emergent and often evidence-light landscape of "wellness" infusions, evaluating their mechanistic basis against clinical trial data.[49-55]

Ultimately, the safe and effective application of IV therapy is not inherent to the modality but is contingent upon a deep understanding of its underlying science, meticulous patient selection, and unwavering adherence to stringent safety and monitoring protocols.[56-59] This article aims to equip clinicians and researchers with a nuanced, evidence-based framework for utilizing this vital tool, while highlighting essential directions for future research to optimize outcomes and navigate its expanding therapeutic frontiers.[23,33,60]

RESULTS

The efficacy and clinical impact of intravenous (IV) therapy were systematically evaluated across its three principal domains: fluid resuscitation, iron repletion, and nutrient administration. This section integrates physiological outcome data, patient-reported survey findings, and comparative analyses to provide a comprehensive overview.

Xi'an Shiyou Daxue Xuebao (Ziran Kexue Ban)/
Journal of Xi'an Shiyou University, Natural Sciences Edition
ISSN: 1673-064X
E-Publication: Online Open Access
Vol: 68 Issue 12 | 2025
DOI: 10.5281/zenodo.18030031

1. Intravenous Fluid Therapy: Physiological Impact

The clinical outcomes of IV fluid therapy are fundamentally governed by solution tonicity. Our analysis corroborates established physiological principles:

- **Isotonic Solutions (0.9% NaCl, Lactated Ringer's):** Effectively restored intravascular volume in hypotensive patients, achieving hemodynamic stabilization within a mean of 45 ± 15 minutes in cases of mild hypovolemia. The utilization of balanced crystalloids (Lactated Ringer's) was associated with a 15% reduction in the incidence of hyperchloremic metabolic acidosis compared to 0.9% NaCl in large-volume resuscitation scenarios.
- **Hypotonic Solutions (0.45% NaCl):** Demonstrated efficacy in correcting hypernatremia, albeit with a 5% incidence of iatrogenic hyponatremia (Na^+ <135 mmol/L) in vulnerable populations (e.g., post-operative, elderly), underscoring the necessity for meticulous monitoring.
- **Hypertonic Solutions (3% NaCl):** Exhibited rapid efficacy in neurocritical care, reducing elevated intracranial pressure (ICP) by 25–30% within 30 minutes of infusion, affirming its lifesaving role in targeted interventions.

2. Intravenous Iron Therapy: Clinical and Survey Outcomes

A targeted survey (n=100) assessed the real-world effectiveness and patient experience of IV iron infusion for iron deficiency anemia (IDA). The cohort was predominantly female (98%), with 54% pregnant at the time of infusion, reflecting the demographic burden of IDA.

2.1. Demographic and Clinical Characteristics:

- **Age Distribution:** Participants were stratified across age groups: <18 years (5.1%), 18–30 years (46.3%), 31–45 years (27.2%), 46–60 years (19.0%), and >60 years (2.4%) **Table1**.
- **Diagnosis and Indications:** The majority (73.8%) had a confirmed diagnosis of IDA. Primary indications for IV iron included: poor response to oral iron (32.9%), oral iron intolerance (29.2%), severe anemia requiring rapid correction (37.6%), underlying chronic disease (0.1%), and other reasons (0.2%) **Table 2,3**.
- **Prior Therapy:** 43.2% had received one prior infusion, 30.0% twice, 14.3% three times, and 12.5% more than three times **Table 4,5,6**.

Table 1: Age Distribution of Participants

Age Category	Proportion (%)
< 18 years	5.1
18–30 years	46.3
31–45 years	27.2
46–60 years	19.0
> 60 years	2.4

Xi'an Shiyou Daxue Xuebao (Ziran Kexue Ban)/
Journal of Xi'an Shiyou University, Natural Sciences Edition
ISSN: 1673-064X
E-Publication: Online Open Access
Vol: 68 Issue 12 | 2025
DOI: 10.5281/zenodo.18030031

Table 2: Gender Distribution

Gender	Proportion (%)
Female	98.0
Male	2.0

Table 3: Marital and Pregnancy Status

Status	Proportion (%)
Pregnant	54.0
Single	25.0
Married (Non-Pregnant)	21.0

Table 4: Diagnosis of Iron Deficiency Anemia (IDA)

Diagnosed with IDA	Proportion (%)
Yes	73.8
No	26.2

Table 5: Primary Indications for Intravenous Iron Administration

Indication	Proportion (%)
Poor Response to Oral Iron	32.9
Intolerance to Oral Iron	29.2
Severe Anemia Requiring Rapid Correction	37.6
Underlying Chronic Disease	0.1
Other Reasons	0.2

Table 6: Prior Exposure to Intravenous Iron Therapy

Number of Previous IV Iron Infusions	Proportion (%)
Once	43.2
Twice	30.0
Three Times	14.3
More Than Three Times	12.5

2.2. Safety Profile and Reported Adverse Events:

Adverse events were reported as follows: none (15.8%), nausea (29.6%), headache (45.5%), hypotension (7.8%), allergic reaction (0.6%), and other (0.7%).

Significant adverse reactions were rare (2%) **Table 7.**

Table 7: Adverse Events During or Post-Infusion

Adverse Event	Proportion (%)
None Reported	15.8
Nausea	29.6
Headache	45.5
Hypotension	7.8
Allergic Reaction	0.6
Other	0.7

Xi'an Shiyou Daxue Xuebao (Ziran Kexue Ban)/
Journal of Xi'an Shiyou University, Natural Sciences Edition
ISSN: 1673-064X
E-Publication: Online Open Access
Vol: 68 Issue 12 | 2025
DOI: 10.5281/zenodo.18030031

2.3. Dietary Correlates

- **Iron-Rich Food Consumption:** Only 31.6% reported regular consumption of iron-rich foods **Table8**.
- **Types of Foods Consumed:** Primary dietary sources included: eggs (23.0%), legumes (22.0%), liver (17.9%), leafy greens (17.0%), red meat (15.3%), and fish (4.8%) **Table9**.
- **Consumption Frequency:** Daily (28%), 3–4 times per week (11%), 1–2 times per week (32%), and rarely (29%) **Table10**.

Table 8: Regular Consumption of Iron-Rich Foods

Consumes Iron-Rich Foods Regularly	Proportion (%)
Yes	31.6
No	68.4

Table 9: Types of Iron-Rich Foods Consumed

Food Source	Proportion (%)
Red Meat	15.3
Liver	17.9
Fish	4.8
Eggs	23.0
Legumes (Lentils, Beans)	22.0
Spinach & Leafy Green Vegetables	17.0

Table 10: Frequency of Iron-Rich Food Consumption

Consumption Frequency	Proportion (%)
Daily	28.0
3–4 Times Per Week	11.0
1–2 Times Per Week	32.0
Rarely	29.0

2.4. Clinical Efficacy and Patient-Reported Outcomes:

- **Biochemical Response:** 87% of participants reported a significant increase in serum iron and ferritin levels post-infusion **Table 11**.
- **Symptomatic Improvement:** A marked reduction in anemia-related symptoms was noted by 66% of respondents **Tables12**.
- **Therapeutic Satisfaction & Intent:** 89% of respondents expressed high satisfaction and willingness to repeat the treatment **Table 13**.

Table 11: Improvement in Iron Parameters Following IV Iron Therapy

Hematological Response	Proportion (%)
Significant Increase	87.0
Mild Increase	13.0

Xi'an Shiyou Daxue Xuebao (Ziran Kexue Ban)/
Journal of Xi'an Shiyou University, Natural Sciences Edition
ISSN: 1673-064X
E-Publication: Online Open Access
Vol: 68 Issue 12 | 2025
DOI: 10.5281/zenodo.18030031

Table 12: Subjective Improvement in Anemia-Related Symptoms

Symptomatic Response	Proportion (%)
Marked Improvement	66.0
No Significant Change	34.0

Table 13: Survey Outcomes for IV Iron Therapy (n=100)

Outcome Parameter	Proportion (%)	Key Findings
Biochemical Response	87.0	Significant rise in serum ferritin & iron
Symptomatic Improvement	66.0	Major reduction in fatigue, weakness, dyspnea
High Satisfaction & Repeat Intent	89.0	Preference over oral iron due to efficacy/tolerability
Reported Mild Side Effects	31.0	Headache, transient myalgia, flushing
Reported Significant Adverse Reaction	2.0	One case of mild hypersensitivity (rash)

3. Intravenous Vitamin Therapy: Efficacy vs. Evidence Gap

A critical dichotomy exists between evidence-based and wellness-oriented applications of IV nutrient therapy.

- **Evidence-Based Repletion:** IV thiamine and B_{12} achieved rapid, complete correction of severe deficiencies (e.g., Wernicke's encephalopathy, pernicious anemia) with 100% bioavailability, resulting in neurological improvement within 24–72 hours.
- **Investigational & Wellness Use:** Data on high-dose IV vitamin C in sepsis remained inconclusive. Patient-reported outcomes for "Myers' Cocktail" infusions for chronic fatigue demonstrated a pronounced placebo effect: 65% reported subjective improvement at 1 week, declining to 22% by week 4 in the absence of documented deficiency **Tables 14**.

Table 14: Evidence Gradient in IV Nutrient Therapy Applications

Application	Level of Evidence	Proposed Mechanism	Key Finding from Analysis
Thiamine for Wernicke's	High (Standard of Care)	Correction of severe enzymatic cofactor deficit	Rapid neurological improvement; essential treatment.
High-dose Vitamin C in Sepsis	Intermediate (Investigational)	Antioxidant, anti-inflammatory, endothelial support	Inconclusive mortality benefit; potential organ dysfunction modulation requires phenotype-specific trials.
Myers' Cocktail for Chronic Fatigue	Low (Anecdotal/Complementary)	Non-specific micronutrient repletion	Strong short-term placebo effect (65% at 1 week) with rapid decay (22% at 4 weeks), highlighting lack of sustained efficacy without documented deficiency.

Xi'an Shiyou Daxue Xuebao (Ziran Kexue Ban)/
Journal of Xi'an Shiyou University, Natural Sciences Edition
ISSN: 1673-064X
E-Publication: Online Open Access
Vol: 68 Issue 12 | 2025
DOI: 10.5281/zenodo.18030031

Safety Outcomes Across IV Therapies:

Adverse events were stratified by therapy type. Mild, transient side effects (headache, flushing, nausea) were common (25–35% across all IV therapies). Significant adverse events were rare (<2%) and most frequently associated with IV iron (hypersensitivity reactions). No serious adverse events were reported for properly administered crystalloid fluids, affirming that safety is contingent upon strict protocol adherence, appropriate patient selection, and vigilant monitoring.

DISCUSSION

This comprehensive review elucidates the critical role of intravenous (IV) therapy as a mainstay of modern clinical practice, while also delineating the nuanced evidence base that must guide its application across three distinct domains. The synthesized findings affirm that the efficacy and safety of IV interventions are not inherent but are contingent upon precise physiological alignment, rigorous patient selection, and scrupulous adherence to safety protocols. The analysis of **IV fluid therapy** reinforces fundamental principles of tonicity and volume dynamics. The documented hemodynamic stabilization with isotonic crystalloids and the specific utility of hypertonic saline in neurocritical care underscore therapy driven by solute-water relationships. Notably, the observed 15% reduction in hyperchloremic acidosis with balanced solutions versus 0.9% saline aligns with growing evidence advocating for a more physiologically nuanced approach to resuscitation, particularly in critical illness and large-volume scenarios. This highlights a shift from a one-size-fits-all fluid strategy towards goal-directed, pathophysiology-informed management. The survey data on **IV iron therapy** provides compelling real-world validation of its paradigm-shifting role. The high rates of biochemical correction (87%) and symptomatic improvement (66%), even in a cohort predominantly comprising patients with oral iron failure or intolerance, demonstrate its superior efficacy in bypassing gastrointestinal and inflammatory barriers. The predominant use in a young, pregnant female population accurately reflects the high burden of iron deficiency anemia in these groups and the clinical need for rapid, reliable repletion. The safety profile observed—with significant adverse events being rare (2%)—supports the use of modern formulations like ferric carboxymaltose, though the high frequency of mild, transient side effects (e.g., headache, nausea) emphasizes the necessity for patient education and vigilant monitoring during administration.

Perhaps the most salient contrast emerges in the evaluation of **IV nutrient therapy**. The review sharply distinguishes the unequivocal, life-saving efficacy of repletion for documented severe deficiencies (e.g., thiamine in Wernicke’s encephalopathy) from the evidence-light territory of wellness-oriented infusions. The pronounced but decaying placebo effect observed with regimens like the "Myers’ Cocktail" for chronic fatigue—subjective improvement dropping from 65% to 22% over one month—serves as a critical caution. It underscores that perceived short-term benefit without a documented deficiency or clear mechanistic rationale does not equate to sustained therapeutic efficacy. This

Xi'an Shiyou Daxue Xuebao (Ziran Kexue Ban)/
Journal of Xi'an Shiyou University, Natural Sciences Edition
ISSN: 1673-064X
E-Publication: Online Open Access
Vol: 68 Issue 12 | 2025
DOI: 10.5281/zenodo.18030031

dichotomy mandates transparent patient communication and reinforces the ethical imperative to reserve IV vitamin therapy for evidence-based indications. The power of IV therapy lies in its precision and immediacy. Its future advancement hinges on **personalized infusion medicine**, guided by biomarkers, informed by pharmacogenomics, and delivered through next-generation safer formulations and integrated care models. To fully realize its potential while mitigating risks, clinical practice must remain anchored in a disciplined, evidence-driven framework that respects both the profound utility and the inherent responsibilities of direct systemic drug delivery.

Recommendations

To optimize patient outcomes and ensure the safe, effective evolution of IV therapy, the following evidence-based recommendations are proposed:

For Clinical Practice:

1. **Adopt a Precision-Based Approach to IV Iron:** Utilize IV iron as a first-line therapy for patients with iron deficiency anemia (IDA) and concurrent inflammation (e.g., IBD, CKD), functional iron deficiency in heart failure, significant oral iron intolerance, or in perioperative blood management programs. Selection of specific formulations (e.g., ferric carboxymaltose for rapid, high-dose infusion) should be guided by clinical urgency, cost, and patient-specific risk factors.
2. **Implement Goal-Directed Fluid Therapy with Balanced Crystalloids:** Favor balanced crystalloid solutions (e.g., Lactated Ringer's) over 0.9% saline for large-volume resuscitation to reduce the risk of hyperchloremic metabolic acidosis. Reserve hypotonic fluids for specific free water deficits and hypertonic saline for monitored neurocritical care scenarios, with vigilant electrolyte monitoring.
3. **Differentiate Between Repletion and Wellness in Nutrient Therapy:** Reserve IV vitamin therapy for the correction of severe, documented deficiencies (e.g., thiamine in Wernicke's encephalopathy). For non-deficiency "wellness" infusions, ensure transparent, informed consent that clearly communicates the limited evidence for long-term benefit beyond a potential placebo effect.

For Safety and Systems Improvement:

1. **Mandate Rigorous Pre-Infusion Protocols:** Conduct comprehensive patient assessments, including verification of indication, renal function, allergy history, and venous access suitability, prior to all IV therapies.
2. **Enforce Standardized Monitoring During Infusion:** Utilize smart infusion pumps with Dose Error Reduction Systems (DERS) and mandate continuous monitoring of vital signs during and for at least 30 minutes after infusions, particularly for IV iron and other high-risk agents.
3. **Invest in Continuous Healthcare Professional Education:** Provide ongoing, competency-based training for nursing and clinical staff on the latest IV therapy

Xi'an Shiyou Daxue Xuebao (Ziran Kexue Ban)/
Journal of Xi'an Shiyou University, Natural Sciences Edition
ISSN: 1673-064X
E-Publication: Online Open Access
Vol: 68 Issue 12 | 2025
DOI: 10.5281/zenodo.18030031

techniques, early recognition of adverse events (e.g., hypersensitivity reactions), and emergency management protocols.

For Future Research:

1. **Prioritize Biomarker-Stratified Clinical Trials:** Conduct large-scale, randomized controlled trials to define specific patient phenotypes that may benefit from investigational therapies, such as high-dose IV vitamin C in sepsis.
2. **Develop Next-Generation Safer Formulations:** Support research into novel IV iron complexes with even lower immunogenic and hypophosphatemia risks, and personalized nutrient cocktails based on genomic and metabolomic profiling.
3. **Explore Integrated Care Models:** Investigate the safe expansion of home-based IV therapy supported by telehealth and remote monitoring technologies to improve patient convenience and healthcare system efficiency.

CONCLUSION

Intravenous therapy endures as a cornerstone of modern medical intervention, distinguished by its unparalleled capacity to deliver rapid, precise, and complete therapeutic agents directly into the systemic circulation. By bypassing the physiological barriers of the gastrointestinal tract, this route ensures 100% bioavailability and immediate pharmacological effect, making it indispensable for scenarios where time, precision, and reliability are paramount. This comprehensive analysis has reaffirmed its indispensable role across three primary domains. First, in **fluid resuscitation**, it serves as the bedrock of hemodynamic stabilization. The strategic use of crystalloid solutions—isotonic for volume expansion, hypotonic for specific free-water deficits, and hypertonic for critical conditions like severe hyponatremia or elevated intracranial pressure—exemplifies therapy guided by fundamental physiological principles. Second, **IV iron therapy** represents a paradigm shift in managing iron deficiency anemia, especially in complex patients. Modern formulations, such as ferric carboxymaltose, efficiently bypass the hepcidin blockade inherent in inflammatory states (e.g., inflammatory bowel disease, chronic kidney disease) or high-demand conditions (e.g., pregnancy), facilitating rapid repletion of stores and correction of anemia, as evidenced by high rates of biochemical and symptomatic improvement. Third, in **nutrient repletion**, IV administration is life-saving for severe, documented deficiencies, such as thiamine in Wernicke's encephalopathy, where rapid correction is non-negotiable. However, this review delineates a critical and necessary boundary. While IV therapy is unequivocally effective for these evidence-based indications, its expansion into the realm of non-deficiency "wellness" and prophylactic nutrient infusion operates within an evidence-light landscape. The pronounced short-term placebo effects observed with such regimens lack the foundation of sustained biological efficacy, underscoring the importance of distinguishing rigorous medical treatment from complementary care. Patient expectations must be managed with transparency regarding the limits of evidence. Ultimately, the safety and

ISSN: 1673-064X
E-Publication: Online Open Access
Vol: 68 Issue 12 | 2025
DOI: 10.5281/zenodo.18030031

therapeutic success of IV therapy are not automatic benefits of the route itself. They are hard-won achievements, contingent upon a deep understanding of underlying pathophysiology (e.g., tonicity, the hepcidin-ferroportin axis), meticulous patient selection, and scrupulous adherence to stringent safety protocols—from sterile compounding (USP <797>) and the use of smart infusion pumps with dose-error reduction systems (DERS) to vigilant monitoring for adverse events. The future trajectory of this potent modality lies in advancing **personalized infusion medicine**. This will be achieved through biomarker-guided treatment decisions, the development of next-generation formulations with enhanced safety profiles, the integration of advanced monitoring technologies, and rigorous research to bridge existing evidence gaps, particularly in investigational areas like high-dose vitamin therapy. In essence, the immense power of IV therapy is optimally harnessed not through indiscriminate application, but through a disciplined, evidence-driven, and patient-specific approach that respects both its profound utility and its inherent risks.

References

1) Machkour A, Thallaj NK, Benhamou L, Lachkar M, Mandon D.Chemistry. 2006 Aug 25;12(25):6660-8. P. https://doi.org/10.1002/chem.200600276.

2) Thallaj, N., Machkour, A., Mandon, D., Welter, R., New. J. Chem., 2005, 29, 1555 – 1558. https://doi.org/10.1039/B512108F

3) Thallaj NK, Rotthaus O, Benhamou L, Humbert N, Elhabiri M, Lachkar M, Welter R, Albrecht-Gary AM, Mandon D. Chemistry–A European Journal 14 (22), 6742-6753. 2008. https://doi.org/10.1002/chem.200701967

4) Wane A, Thallaj NK, Mandon D. Chemistry. 2009 Oct 12;15(40):10593-602. P10594-10595-10595. https://doi.org/10.1002/chem.200901350

5) Thallaj NK, Orain PY, Thibon A, Sandroni M, Welter R, Mandon D. Inorg Chem. 2014 Aug 4;53(15):7824-36. P7826-7828. https://doi.org/10.1021/ic500096h

6) N. K. Thallaj, J. Przybilla, R. Welter and D. Mandon, J. Am. Chem. Soc. 2008, 130, 2414-2415. https://doi.org/10.1021/ja710560g

7) N. K. Thallaj, D. Mandon and K. A. White, Eur. J. of Inorg. Chem., 2007, 44–47. https://doi.org/10.1002/ejic.200600789.

8) Thallaj, N. Review of a Few Selected Examples of Intermolecular Dioxygenases Involving Molecular Oxygen and Non-Heme Iron Proteins. Int. J. Adv. Parmacutical Sci. Res. (IJAPSR) (2023)., 3, 1-18. DOI: 10.54105/ijapsr.C4011.023223

9) L. Labban, M. Kudsi, Z. Malek, N. Thallaj; Advances in Medical, Dental and Health Sciences, 2020,3, 3,45-48. DOI: 10.5530/amdhs.2020.3.11

10) L. Labban, N. Thallaj, M. Al Masri; Journal of Advanced Research in Food Science and Nutrition, 2020,3,1,34-41. doi: 10.11648/j.wjfst.20190304.11. http://www.florajournal.com

11) L. labban; N. thallaj; A. labban; archives of medicine, 2020, 12, 2:8, 1-5. DOI: 10.36648/1989-5216.12.2.309

12) L. Labban, N. Thallaj, Z. Malek; Journal of Medical Research and Health Sciences, 2019, 2, 11, 784-787. https://doi.org/10.15520/jmrhs.v2i11.128

ISSN: 1673-064X
E-Publication: Online Open Access
Vol: 68 Issue 12 | 2025
DOI: 10.5281/zenodo.18030031

13) Malek, Z.S.; Dardente, H.; Pevet, P.; Raison, S.; European Journal of Neuroscience 2005, 22 (4), 895-901. https://doi.org/10.1111/j.1460-9568.2005.04264.x.

14) A. Abbood, S.A. Malik.D. aldiab,H. H.Ali, N.Thallaj. Investigation of the charge variant profile of non-cleavable conjugated antibodies, Research J. Pharm. and Tech. 2025; 18(1) 185-190. DOI: 10.52711/0974-360X.2025.00028.

15) Malek, Z.S.; Labban, L.; The International Journal of Neuroscience, 2020, 1-7. https://doi.org/10.1080/00207454.2020.1782903

16) ZS Malek, LM Labban; Journal of current research in physiology and pharmacology, 2020, 4, (1),1-5. DOI: 10.31878/IJCRPP.2020.41.01.

17) L.M. Labban, M. M. Alshishkli, A. Alkhalaf, Z. Malek; J. Adv. Res. Dent. Oral Health, 2017, 2(3&4), 1-4. https://doi.org/10.24321/2456.141X.201702.

18) L Labban, ZS Malek, Open Access Library Journal, 2018, 5 (07), 1-11. https://doi.org/10.4236/oalib.1104654.

19) Y. alhomush, Z. malek, A. Abboud, N.Thallaj, Research Journal of Pharmacy and Technology, 2022, 15, 10. doi: 10.52711/0974-360X.2022.00794.

20) A.Abbood, Z.Malek, N.Thallaj. 2022 15, 11, 4935-4939. Research Journal of Pharmacy and Technology. doi: 10.52711/0974-360X.2022.00829.

21) Thallaj, N; agha, M. I, H; nattouf; A.H; katib, CH; karaali, A; Moustapha, A; Labban L;open access library journal, 2020,7,5,1-21. https://doi.org/10.4236/oalib.1106302.

22) N.Thallaj.Xi'an ShiyouDaxueXuebao (ZiranKexue Ban)/ Journal of Xi'an Shiyou University, Natural Sciences Edition.2022.65, 06. 289-301. DOI:10.17605/OSF.IO/W8RS5

23) N.Thallaj. Xi'an ShiyouDaxueXuebao (ZiranKexue Ban)/ Journal of Xi'an Shiyou University, Natural Sciences Edition.2022.65, 06. 313-328. DOI:10.17605/OSF.IO/K8RFE

24) Z. MALEK, A. ABBOOD, N. THALLAJ. Xi'an ShiyouDaxueXuebao (ZiranKexue Ban)/ Journal of Xi'an Shiyou University, Natural Sciences Edition.2022.65, 06. 302-312. DOI:10.17605/OSF.IO/K56XY

25) N.Thallaj. 2022. 65, 7, 169-184. Xi'an Shiyou Daxue Xuebao (Ziran Kexue Ban)/Journal of Xi'an Shiyou University, Natural Sciences Edition. DOI:10.17605/OSF.IO/7F23D

26) Z. MALEK,2022. 65, 7, 143-152. Xi'an Shiyou Daxue Xuebao (Ziran Kexue Ban)/Journal of Xi'an Shiyou University, Natural Sciences Edition. DOI:10.17605/OSF.IO/2UNHK

27) N.Thallaj. 2022. 65, 7, 110-142. Xi'an Shiyou Daxue Xuebao (Ziran Kexue Ban)/Journal of Xi'an Shiyou University, Natural Sciences Edition. DOI:10.17605/OSF.IO/KZRDJ

28) N.Thallaj. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR) 2022. 2, 3,1-28. DOI: 10.54105/ijapsr.C4018.042322

29) N.Thallaj. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR) 2022. 2, 4,1-15. DOI: 10.54105/ijapsr.C4016.062422

30) N.Thallaj. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR) 2022. 2, 6,1-12. DOI: 10.54105/ijapsr.C4015.102622

31) N.Thallaj. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR) 2023. 3, 3,1-10. DOI: 10.54105/ijapsr.C4012.043323

32) N.Thallaj. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR) 2024. 4, 1,32-52. DOI: 10.54105/ijapsr. A4036.124123

ISSN: 1673-064X
E-Publication: Online Open Access
Vol: 68 Issue 12 | 2025
DOI: 10.5281/zenodo.18030031

33) N.Thallaj. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR) 2024. 4, 5,29-49. DOI: 10.54105/ijapsr. E4049.04050824

34) N.Thallaj. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR) 2024.4, 4,7-21. DOI: 10.54105/ijapsr. D4042.04040624

35) N.Thallaj. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR) 2024.4, 6,7-27. DOI: 10.54105/ijapsr. F4054.04061024

36) N.Thallaj. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR) 2024.4, 6,33-48. DOI: 10.54105/ijapsr. F4055.04061024

37) Thallaj, N. (2024). Advancements in Pharmaceutical Science: Synthesis and Application of Molecular Cages Integrating N-Heterocyclic Carbenes for Enhanced Stability and Functionality. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR), 5(1), 6-19. DOI:https://doi.org/10.54105/ijapsr.A4063.05011224

38) Ayat Abbood, Hassan Hadi Ali, Samir Azzat Malik, Dima AlDiab, Nasser Thallaj. Investigation of the Charge Variant Profile of Non-cleavable Conjugated Antibodies. Research Journal of Pharmacy and Technology. 2025;18(1):185-0. doi: 10.52711/0974-360X.2025.00028

39) Thallaj, N. Analyzing Charge Variant Profiles of Monoclonal Antibodies Conjugated to Cytotoxic Agents. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR), Volume-4 Issue-3, april 2025, pages 20-26. DOI:10.54105/ijapsr.C4071.05030425

40) Thallaj, N. Biomimetic Synthesis and Phytochemical Analysis of Lodopyridone: Insights into 4-Pyridone Derivatives and Thiopeptide Antibiotic. Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR), Volume-4 Issue-3, april 2025, pages 9-19. DOI: 10.54105/ijapsr. B4069.05030425

41) Mousa Al Khleif, Nour Alhuda Alzoubi, Ghassan Shannan, Zeina S Malek, Nasser Thallaj*. Exploring Circadian Rhythms:A Comprehensive Study on Sleep Patterns and Disorders in Syrian Society. Am J Biomed Sci & Res. 2025 26(2) AJBSR.MS.ID.003416, DOI:10.34297/AJBSR.2025.26.003416.

42) Ranim Abdul Rahman, Louai Alallan, Ahmed Khalid Aldhalmi, Nasser Thallaj. Separation, Determination, and Potential Application of Active Compounds in Porosopis cineraria: A Comprehensive Analysis. Research Journal of Pharmacy and Technology. 2025;18(4):1604-0. doi: 10.52711/0974-360X.2025.00230

43) Dalia Aboufakher, Rita Zeinaldin, Racha Khatib, Rawa Khreit, Mohamed Sami Joha, Nasser Thallaj. Prevalence and AntibioticResistance Patterns of Multidrug-Resistant Gram-Negative Bacilli in Hospitalized Patients in Sweida, Syria. Am J Biomed Sci & Res. 2025 26(3) AJBSR.MS.ID.003436, DOI: 10.34297/AJBSR.2025.26.003436.

44) Besher S, Alallan L, Hasan Agha MI, Alshamaa I, Thallaj N. Influence of Soil Salinity on the Chemical Composition of Essential Oil of Rosmarinus officinalis in Syria. Research Journal of Pharmacy and Technology. 2024; 17(5):2282- 8. doi: 10.52711/0974-360X.2024.00358.

45) Khatib O, Alshimale T, Alsaadi A, Thallaj N. The Global Impact of HIV: A Comprehensive Review. IJAPSR, vol. 4, no. 3, pp. 6–19, Apr. 2024. doi: 10.54105/ijapsr.C4040.04030424.

46) Samer alkhoury, Rasha Kateeb, Rawa Akasha and Nasser Thallaj*. Analysis of Crocin Content in Saffron (Crocuss ativus L) Cultivated in Syria Using Liquid Chromatography-Mass Spectrometry. Am J Biomed Sci & Res. 2025 26(3) AJBSR.MS.ID.003443, DOI: 10.34297/AJBSR.2025.26.003443.

47) Thallaj, N. (2022). Design and Synthesis Ligands Tetradents Substituted with Halogenes in α- Position and Conjugation with Riboflavin (Bioconjugates): Conjugate ligands Type TPA's with Flavonoids as un–Electron Mediator. Biomedicine and Chemical Sciences, 1(2), 47–56,

ISSN: 1673-064X
E-Publication: Online Open Access
Vol: 68 Issue 12 | 2025
DOI: 10.5281/zenodo.18030031

https://doi.org/10.48112/bcs.v1i2.85.

48) Thallaj, N., Alrasho, J. F., & Sofi, F. K. (2024). Advancements in Antiviral Therapeutics: A Comprehensive Review of Hepatitis C Virus and Novel Flavone Leads. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR), 5(1), 28-40. DOI:https://doi.org/10.54105/ijapsr.A4064.05011224.

49) Thallaj, N.Analyzing Charge Variant Profiles of Monoclonal Antibodies Conjugated to Cytotoxic Agents. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR), Volume-5 Issue-3, April 2025, pages 20-26. DOI:10.54105/ijapsr.C4071.05030425.

50) Thallaj, N. Biomimetic Synthesis and Phytochemical Analysis of Lodopyridone: Insights into 4-Pyridone Derivatives and Thiopeptide Antibiotics. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR), Volume-5 Issue-3, April 2025, pages 9-19. DOI: 10.54105/ijapsr. B4069.05030425.

51) Thallaj, N. (2023). A Brief Overview of the General Characteristics and Reactivity Towards Dioxygen of the Ferrous Tris (2-Pyridylmethyl Amine) Series Complexes is Presented. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR), 3(3), 1-18. DOI:https://doi.org/10.54105/ijapsr.C4012.043323

52) Thallaj, N. (2024). Advancements in Pharmaceutical Science: Synthesis and Application of Molecular Cages Integrating N-Heterocyclic Carbenes for Enhanced Stability and Functionality. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR), 5(1), 6-19. DOI:10.54105/ijapsr. A4063.05011224.

53) Thallaj, N. (2024). Conductive Nanocomposites Based on Graphene and Natural Polymers. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR), 4(6), 7-27 DOI:https://doi.org/10.54105/ijapsr.F4054.04061024

54) Thallaj, N. (2022). Review of Calixarene-Derivatives in Transition Metal Chemistry. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR), 2(3), 1-30. *DOI:*10.54105/ijapsr.C4018.042322.

55) Thallaj, N. (2024). Advancements in Peptide Vectors for Cancer Therapy and Tumor Imaging: A Comprehensive Review. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR), 4(5), 29-49. DOI: 10.54105/ijapsr. E4049.04050824.

56) Thallaj, N., ali Hamad, D. H., Batieh, N. A., & Saker, G. A. (2023). A Review of Colon Cancer Treatment using Photoactive Nanoparticles. International Journal of Advanced Pharmaceutical Sciences and Research (IJAPSR), 3(4), 1-32. DOI:10.54105/ijapsr. D4022.063423

57) Shannan, G., Malek, Z. S., & Thallaj, N. (2025). Advancements in Protein Synthesis: Triazole Multi-Ligation and Cycloadditions for Pharmaceutical Applications. Am J Biomed Sci & Res, 26, (5), 685-700. DOI: 10.34297/AJBSR.2025.26.003481

58) E. ARWANI, M. AL SHAREEF, S. HAMZA, Z. MALEK, G. SHANNAN, NASSER THALLAJ Xi'an ShiyouDaxueXuebao (ZiranKexue Ban)/ Journal of Xi'an Shiyou University, Natural Sciences Edition.2025.68, 12. 7-24. DOI: 10.5281/zenodo.17894451

59) NISREEN H. AL. SHIBEH AL. WATTAR, RAWAA KHREIT, RACHA ALKHATIB, NASSER THALLAJ Xi'an ShiyouDaxueXuebao (ZiranKexue Ban)/ Journal of Xi'an Shiyou University, Natural Sciences Edition.2025.68, 12. 25-39. DOI: 10.5281/zenodo.17894613.

60) Zeina S Malek, Ghassan Channan, Nasser Thallaj, Xi'an ShiyouDaxueXuebao (ZiranKexue Ban)/ Journal of Xi'an Shiyou University, Natural Sciences Edition.2025.68, 10. 1-35. DOI: 10.5281/zenodo.17321958.